Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tudor-Eliade Ciuleanu

Showing results (51-60 of 66) with videos related to

Pageof 7
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 12, 2022
Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227Julie R Brahmer, Jong-Seok Lee, Tudor-Eliade Ciuleanu, et al.
Journal for Immunotherapy of Cancer|August 6, 2024
Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burdenMichael Schenker, Mauricio Burotto, Martin Richardet, et al.
The Lancet. Oncology|January 21, 2021
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trialLuis Paz-Ares, Tudor-Eliade Ciuleanu, Manuel Cobo, et al.
The New England Journal of Medicine|June 2, 2025
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based ChemotherapyGiannis Mountzios, Longhua Sun, Byoung Chul Cho, et al.
The New England Journal of Medicine|June 2, 2025
Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung CancerPatrick M Forde, Jonathan D Spicer, Mariano Provencio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2026
Early Detriment Analysis of First-Line Nivolumab plus Ipilimumab-Based Therapy in Patients with Metastatic Non-Small Cell Lung CancerHossein Borghaei, David Balli, Luis G Paz-Ares, et al.
The New England Journal of Medicine|April 11, 2022
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung CancerPatrick M Forde, Jonathan Spicer, Shun Lu, et al.
Future Oncology (London, England)|February 23, 2023
Plain language summary of the CheckMate 816 study results: nivolumab plus chemotherapy given before surgery for non-small-cell lung cancerPatrick M Forde, Jonathan Spicer, Shun Lu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 1, 2022
Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817Luis G Paz-Ares, Tudor-Eliade Ciuleanu, Adam Pluzanski, et al.
Journal for Immunotherapy of Cancer|February 1, 2023
First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817Neal E Ready, Clarisse Audigier-Valette, Jonathan W Goldman, et al.
Pageof 7

Showing results (51-60 of 66) with videos related to

Sort By:
Pageof 7
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 12, 2022
Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227Julie R Brahmer, Jong-Seok Lee, Tudor-Eliade Ciuleanu, et al.
Journal for Immunotherapy of Cancer|August 6, 2024
Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burdenMichael Schenker, Mauricio Burotto, Martin Richardet, et al.
The Lancet. Oncology|January 21, 2021
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trialLuis Paz-Ares, Tudor-Eliade Ciuleanu, Manuel Cobo, et al.
The New England Journal of Medicine|June 2, 2025
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based ChemotherapyGiannis Mountzios, Longhua Sun, Byoung Chul Cho, et al.
The New England Journal of Medicine|June 2, 2025
Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung CancerPatrick M Forde, Jonathan D Spicer, Mariano Provencio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2026
Early Detriment Analysis of First-Line Nivolumab plus Ipilimumab-Based Therapy in Patients with Metastatic Non-Small Cell Lung CancerHossein Borghaei, David Balli, Luis G Paz-Ares, et al.
The New England Journal of Medicine|April 11, 2022
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung CancerPatrick M Forde, Jonathan Spicer, Shun Lu, et al.
Future Oncology (London, England)|February 23, 2023
Plain language summary of the CheckMate 816 study results: nivolumab plus chemotherapy given before surgery for non-small-cell lung cancerPatrick M Forde, Jonathan Spicer, Shun Lu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 1, 2022
Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817Luis G Paz-Ares, Tudor-Eliade Ciuleanu, Adam Pluzanski, et al.
Journal for Immunotherapy of Cancer|February 1, 2023
First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817Neal E Ready, Clarisse Audigier-Valette, Jonathan W Goldman, et al.
Pageof 7